The invention claimed is:

1. A crystalline form of co-crystals of agomelatine and *p*-toluenesulphonic acid of formula (I):



(I)

wherein n represents 0 or 1.

2. The crystalline form according to claim 1, which is the co-crystal of agomelatine and *p*-toluenesulphonic acid monohydrate, having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity:

2-Theta (°) exp.	d (Å) exp.	Intensity (%)
6.9631	12.6846	77.52
9.4831	9.31871	16.21
12.8823	6.86648	100
13.9527	6.34201	23.16
14.1761	6.24258	16.06
15.1817	5.83128	13.38
15.379	5.75689	25
15.5788	5.68351	46.24
16.7156	5.29947	94.46
17.2926	5.12391	37.98
18.4671	4.80058	92.47
18.6356	4.75756	22.34
19.199	4.6192	25.69
19.6747	4.50857	35.74
20.1398	4.4055	28.53
21.6248	4.1062	14.93
22.0586	4.02643	52.23
22.2859	3.98587	99.09
23.2175	3.82799	15.22
23.9607	3.71092	32.37
25.1733	3.53485	42.09
26.0152	3.42233	16.64
27.7148	3.2162	39.29

28.23	3.15866	11.25
28.4033	3.13979	16.33

including the forms whose diffraction angles correspond to within ±0.2°.

3. The crystalline form according to claim 1, which is the co-crystal of agomelatine and *p*-toluenesulphonic acid, having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity:

2-Theta (°) exp.	d (Å) exp.	Intensity (%)
11.2964	7.82664	21.53
11.6596	7.58367	20.45
13.4436	6.58103	61.31
15.2416	5.80848	18.42
16.0185	5.52847	30.89
17.3473	5.10789	41.39
17.8289	4.97096	54.3
18.2535	4.85629	100
20.4891	4.33118	19.84
20.6912	4.28932	45.12
20.9516	4.23659	36.73
21.3088	4.16638	14.93
22.2998	3.98342	33.92
23.129	3.84244	24.66
23.4107	3.79685	12.89
23.6474	3.75938	12.34
23.9983	3.7052	12.8

including the forms whose diffraction angles correspond to within ±0.2°.

4. A process for obtaining the co-crystals of agomelatine and *p*-toluenesulphonic acid according to claim 1, wherein:

- agomelatine and *p*-toluenesulphonic acid monohydrate are mixed in an organic or aqueous-organic solvent in the desired proportions;
- the solution obtained is stirred and optionally heated at a temperature not greater than the boiling point of the chosen solvent;
- the mixture is cooled, with stirring, and the complex precipitates naturally or precipitates after being taken up in a second solvent;

- the precipitate obtained is filtered and dried;
- optionally, the precipitate is dried by heating.

5. A process for the preparation of the co-crystals of agomelatine and *p*-toluenesulphonic acid according to claim 1, wherein the two constituents are co-ground.

6. A process for the preparation of the co-crystals of agomelatine and *p*-toluenesulphonic acid according to claim 1, wherein the two constituents are mixed in an organic or aqueous-organic solvent and then frozen and dried at a very low temperature.

7. A process for the preparation of the co-crystals of agomelatine and *p*-toluenesulphonic acid according to claim 1, wherein the powders of agomelatine and the acid in question are mixed in a mixer and the mixture is then extruded by twin-screw extrusion without a die in order to obtain a solid grain directly at the outlet of the extruder.

8. A pharmaceutical composition comprising as active ingredient the co-crystals of agomelatine and *p*-toluenesulphonic acid according to claim 1, in combination with one or more inert, non-toxic, pharmaceutically acceptable carriers.